Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 22 | 2026 | 635 | 5.410 |
Why?
|
| Early Detection of Cancer | 11 | 2026 | 418 | 2.070 |
Why?
|
| Occult Blood | 9 | 2026 | 32 | 1.940 |
Why?
|
| Colonoscopy | 9 | 2022 | 246 | 1.740 |
Why?
|
| Colonic Neoplasms | 6 | 2024 | 265 | 1.270 |
Why?
|
| Adenoma | 3 | 2022 | 145 | 1.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2025 | 204 | 0.970 |
Why?
|
| Lymphocytes | 3 | 2023 | 347 | 0.920 |
Why?
|
| Mass Screening | 7 | 2022 | 808 | 0.820 |
Why?
|
| Colonic Polyps | 2 | 2021 | 85 | 0.740 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 14 | 0.690 |
Why?
|
| Polyps | 1 | 2021 | 40 | 0.670 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 1307 | 0.630 |
Why?
|
| Anemia | 2 | 2023 | 355 | 0.580 |
Why?
|
| Guaiac | 1 | 2017 | 1 | 0.530 |
Why?
|
| Xylenes | 4 | 2007 | 13 | 0.510 |
Why?
|
| Prognosis | 9 | 2023 | 4934 | 0.500 |
Why?
|
| Inflammation | 3 | 2024 | 1490 | 0.490 |
Why?
|
| Body Composition | 3 | 2024 | 548 | 0.480 |
Why?
|
| Anti-Infective Agents, Local | 5 | 2007 | 69 | 0.470 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 11 | 0.410 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2022 | 19 | 0.360 |
Why?
|
| Diabetes Complications | 1 | 2013 | 199 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 217 | 0.360 |
Why?
|
| Aspirin | 1 | 2013 | 216 | 0.350 |
Why?
|
| Neutrophils | 3 | 2023 | 364 | 0.350 |
Why?
|
| Aged | 15 | 2026 | 20958 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 300 | 0.340 |
Why?
|
| Trypsin | 1 | 2010 | 66 | 0.330 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 33 | 0.330 |
Why?
|
| Humans | 38 | 2026 | 130776 | 0.320 |
Why?
|
| Catheters | 1 | 2010 | 84 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 451 | 0.320 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 234 | 0.310 |
Why?
|
| Drug Utilization | 1 | 2011 | 161 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 6 | 2011 | 2550 | 0.310 |
Why?
|
| Hemoglobins | 3 | 2026 | 287 | 0.300 |
Why?
|
| Feces | 4 | 2026 | 723 | 0.290 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 251 | 0.290 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 481 | 0.280 |
Why?
|
| Thymol | 1 | 2007 | 2 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2104 | 0.270 |
Why?
|
| Middle Aged | 13 | 2026 | 28499 | 0.270 |
Why?
|
| Retrospective Studies | 9 | 2026 | 17674 | 0.270 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 71 | 0.260 |
Why?
|
| Pneumonia | 1 | 2011 | 342 | 0.260 |
Why?
|
| Equipment Contamination | 2 | 2005 | 40 | 0.250 |
Why?
|
| Chlorhexidine | 5 | 2006 | 47 | 0.250 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 212 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 748 | 0.240 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 987 | 0.240 |
Why?
|
| Male | 19 | 2026 | 64680 | 0.240 |
Why?
|
| Escherichia coli | 2 | 2010 | 984 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3114 | 0.240 |
Why?
|
| Female | 22 | 2026 | 70630 | 0.230 |
Why?
|
| Prosthesis-Related Infections | 3 | 2005 | 184 | 0.230 |
Why?
|
| Glycopeptides | 1 | 2005 | 26 | 0.230 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 893 | 0.220 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 327 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2307 | 0.220 |
Why?
|
| Referral and Consultation | 2 | 2026 | 559 | 0.220 |
Why?
|
| Vancomycin | 1 | 2005 | 219 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1422 | 0.190 |
Why?
|
| Scotland | 3 | 2021 | 24 | 0.190 |
Why?
|
| Staphylococcal Infections | 3 | 2005 | 564 | 0.190 |
Why?
|
| United Kingdom | 2 | 2013 | 253 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2021 | 6494 | 0.170 |
Why?
|
| Logistic Models | 2 | 2018 | 1824 | 0.170 |
Why?
|
| Age Factors | 3 | 2024 | 2849 | 0.170 |
Why?
|
| Sex Factors | 2 | 2016 | 1341 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2021 | 1512 | 0.160 |
Why?
|
| Candida albicans | 4 | 2007 | 87 | 0.160 |
Why?
|
| Morbidity | 1 | 2021 | 261 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 6241 | 0.160 |
Why?
|
| Rabbits | 6 | 2007 | 572 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 2126 | 0.150 |
Why?
|
| Rectal Neoplasms | 2 | 2024 | 78 | 0.140 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1998 | 4 | 0.140 |
Why?
|
| Emergencies | 2 | 2016 | 178 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 326 | 0.130 |
Why?
|
| Spain | 1 | 2017 | 59 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 167 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 691 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2022 | 1685 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 73 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 87 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1076 | 0.120 |
Why?
|
| Minocycline | 4 | 2002 | 43 | 0.120 |
Why?
|
| Pregnancy, Twin | 1 | 2017 | 191 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 6 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1388 | 0.110 |
Why?
|
| Rifampin | 4 | 2002 | 122 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1408 | 0.110 |
Why?
|
| Iron | 1 | 2018 | 305 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12910 | 0.110 |
Why?
|
| Colon | 1 | 2017 | 356 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 2145 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 6784 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2007 | 843 | 0.100 |
Why?
|
| Obesity | 1 | 2025 | 2389 | 0.100 |
Why?
|
| Catheters, Indwelling | 3 | 2007 | 148 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 49 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 539 | 0.090 |
Why?
|
| Length of Stay | 2 | 2024 | 1398 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1224 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 736 | 0.090 |
Why?
|
| Sonication | 1 | 2010 | 7 | 0.080 |
Why?
|
| Colectomy | 2 | 2024 | 90 | 0.080 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 345 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 2 | 2002 | 39 | 0.080 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2002 | 38 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1272 | 0.080 |
Why?
|
| Algorithms | 1 | 2016 | 1677 | 0.080 |
Why?
|
| Adult | 5 | 2024 | 31269 | 0.070 |
Why?
|
| Candidiasis | 2 | 2007 | 131 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 58 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3716 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2011 | 401 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 305 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 5089 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 232 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 1000 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5230 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2007 | 83 | 0.060 |
Why?
|
| Antisepsis | 1 | 2006 | 7 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 2007 | 324 | 0.060 |
Why?
|
| Disinfectants | 1 | 2006 | 28 | 0.060 |
Why?
|
| Candida | 1 | 2006 | 77 | 0.060 |
Why?
|
| Teicoplanin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 265 | 0.060 |
Why?
|
| Bacteria | 1 | 2007 | 538 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 631 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 25 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 489 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 65 | 0.050 |
Why?
|
| Bacterial Adhesion | 3 | 1998 | 104 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 262 | 0.040 |
Why?
|
| Demography | 1 | 2022 | 239 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 118 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 248 | 0.040 |
Why?
|
| Animals | 7 | 2007 | 33891 | 0.040 |
Why?
|
| Catheterization, Central Venous | 2 | 1998 | 142 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1998 | 31 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 39 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 27 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 21 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2024 | 552 | 0.040 |
Why?
|
| Blood | 1 | 1998 | 99 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1998 | 64 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 130 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 600 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1997 | 61 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 46 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 33 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 1997 | 86 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1998 | 175 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 92 | 0.030 |
Why?
|
| Equipment Design | 1 | 1998 | 547 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 137 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 492 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 141 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 426 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 904 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 11003 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1993 | 45 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2017 | 435 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 643 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2014 | 361 | 0.020 |
Why?
|
| Monocytes | 1 | 1993 | 335 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1993 | 262 | 0.020 |
Why?
|
| Pregnancy | 2 | 2017 | 7499 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1993 | 709 | 0.020 |
Why?
|
| Silver Sulfadiazine | 2 | 1998 | 9 | 0.020 |
Why?
|
| Colony Count, Microbial | 2 | 1998 | 85 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1164 | 0.020 |
Why?
|
| Drug Combinations | 2 | 1998 | 278 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 232 | 0.010 |
Why?
|
| Bacillus | 1 | 2002 | 37 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 10021 | 0.010 |
Why?
|
| Drug Stability | 1 | 1998 | 56 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 4664 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 122 | 0.010 |
Why?
|
| Mannose | 1 | 1997 | 22 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 116 | 0.010 |
Why?
|
| Fimbriae, Bacterial | 1 | 1997 | 40 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 422 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 47 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 1997 | 108 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1998 | 614 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 150 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 1996 | 46 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 1996 | 74 | 0.010 |
Why?
|
| Cross Infection | 1 | 1997 | 331 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 1997 | 277 | 0.010 |
Why?
|
| Ganglia, Parasympathetic | 1 | 1993 | 1 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 1457 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1993 | 38 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 79 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1993 | 125 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1478 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1993 | 133 | 0.010 |
Why?
|
| Microglia | 1 | 1993 | 140 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 13323 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 2905 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1993 | 658 | 0.000 |
Why?
|
| Texas | 1 | 1998 | 3634 | 0.000 |
Why?
|
| Adolescent | 1 | 2007 | 20832 | 0.000 |
Why?
|